Corning (GLW) Invests Heavily in Life Sciences
Corning (GLW: Charts, News), a 160-year old company that has dominated several eras with cutting edge technologies, is a controversial stock that splits bulls and bears evenly down the middle. The stock has seen some incredible highs, peaking at $113 in September 2000, and some pitiful lows, hitting $1 per share two years later, in October 2002.
To understand Corning, investors need to understand its history. Originally founded as a glass company in Corning, New York in 1851, Corning moved on to develop ceramics inventions, which became the company's bread and butter between 1913 and the 1970s. Following World War II, Corning focused on disruptive technologies, which could catch industry peers off guard by creating previously non-existent markets. From 1968 to 1971, Corning focused on toughened windshields, which it believed would revolutionize auto windshields worldwide. Unfortunately, the windows were too expensive and never reached the mass production goals that Corning envisioned. Despite this massive failure and the decline of its ceramics business, Corning bounced back from the brink just in time with revolutionary advances in optics technology. From the 1970s to 1990s, this business replaced its ceramics business as its main source of revenue, and eventually produced cutting edge fiber optics which were essential for telecommunications and networking. With the rapid evolution of the Internet, Corning was poised to capitalize on the increasing demand for high speed fiber optic cables. However, the 2000-2002 dot com crash changed all that, decimating not only Corning but most of its industry peers. Investors had all but given up on Corning when it surprisingly pulled back from the brink of bankruptcy, again, to become the world's largest producer of LCD displays. Although shares were nowhere close to its dizzying 2000 highs, the company continued to recover from 2002 to 2007, posting five consecutive years of financial improvement.
The company's talent for coming in with a completely different product to replace an aging one is what excites investors about Corning. It's no secret that the LCD display market is dismal, due to poor margins and pricing power, and investors are looking to Corning once again to change the company's direction in a radically new profitable direction. Over the past five years, Corning has invested heavily in its Life Sciences division, producing two major inventions over the past five years. In 2007, Corning Life Sciences made a drug discovery which reduced drug testing errors drastically, and in 2010 it revolutionized the stem cell experimentation process by producing better results at a lower cost. In June 2011, the company hired Dr. Richard Elgen as vice president and general manager of the Corning Life Sciences business segment, hinting at accelerating growth in the division. On December 1, the company acquired MediaTech, a manufacturer of cell culture media and molecular biology reagents, for an undisclosed amount. The following week, Corning appointed Richard Clark, the former CEO of pharmaceutical giant Merck MRK, to its board of directors, further suggesting that the company was getting ready for a major shift towards biotechnology and pharmaceuticals. Corning has also been aggressively hiring for its Life Sciences division, suggesting that the division may soon become more important than its primary revenue generator of display technologies.
For long-term investors, the message is clear - with the exception of its big bet on stronger windshields four decades ago, every major paradigm shift Corning has made over the past century has been successful and redefined the company. However, the stock has remained in neutral due to shortsighted investors focusing on the weaknesses of its Samsung Corning (LCD displays) and Dow Corning (silicon products) joint ventures. In particular, weakness in Europe's solar industry has severely hurt demand for Dow Corning's polysilicon components, which are key materials in the production of solar modules. If Corning continues to increase the weight of its Life Sciences division, investors should watch carefully for the next stage of the company's evolution, as it dumps unprofitable businesses and shifts into yet another new industry.
Other News About GLW
Corning Worth $16.50 Despite U.S.-China Trade Spats, Euro Mess
The bullish case for Corning, as analyzed by Trefis.
Corning Is Making A Big Bet On Life Sciences
Why is Corning investing so heavily on Life Sciences? Other Stocks in the News
DuPont Is A Great Buy-And-Hold-Forever Stock
Will 2012 be a great year for DuPont?
Halliburton Has At Least 100% Upside Potential
Can Halliburton bounce back, despite recent troubles?
Copyright 2011 by InvestorGuide.com, Inc. InvestorGuide has no control over the sites we link to, is not affiliated with these sites, and cannot take responsibility for their quality or suitability. The news, analysis, commentary and profile information is not meant to be comprehensive, and the data provided is not guaranteed to be accurate. WebFinance Inc., the publisher of this newsletter, is not a registered investment advisor or a broker/dealer. This is not a stock recommendation newsletter but rather a source for investment ideas, and we encourage you to fully research any company before considering investing. The opinions expressed herein are those of the author and do not necessarily represent the views of nor are they endorsed by WebFinance Inc. No employee of WebFinance has owned or currently owns any shares in the company described above. The above is neither an offer nor solicitation to buy or sell any securities. The trading of securities may not be suitable for all potential readers of this newsletter, and the purchase of stocks mentioned in this newsletter may result in the loss of some or all of any investment made. We recommend that you consult a stockbroker or financial advisor before buying or selling securities or making investment decisions. We are not responsible for claims made by advertisers and sponsors. Anyone who makes decisions based on what they read here does so at their own risk and cannot hold WebFinance Inc. (DBA InvestorGuide.com, Inc.) or its employees responsible.